Peptides are notoriously difficult to swallow as pills. They are proteins at heart, and the digestive system treats proteins as food, breaking them apart before they can reach the bloodstream. That is why most peptide drugs have traditionally been given by injection, where they bypass the gut entirely. For patients who need a medication every day or every week for years, injections are a real burden, and researchers have spent decades looking for a workaround.
A recent study published in a European pharmaceutics journal tackled this problem for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used in type 2 diabetes treatment. The research team developed a two-step chemical packaging strategy designed to protect the peptide from gut enzymes and help it slip through the intestinal wall. The results in cell models and diabetic rats were promising enough to draw attention from the peptide formulation field.
The core problem with oral peptides
Semaglutide is a GLP-1 receptor agonist, meaning it mimics a naturally occurring gut hormone that signals to the pancreas and brain after a meal. In its injectable form it has high bioavailability, meaning most of what is injected reaches its target. But swallowing it creates two immediate obstacles.
First, the peptide is hydrophilic, which means it dissolves easily in water but does not cross the fatty lipid membranes that line the intestine very well. Second, digestive enzymes in the stomach and small intestine are specifically designed to cut apart structures like peptides. Together, these two barriers mean that only a tiny fraction of an oral peptide dose would normally reach circulation. The researchers describe this as 'limited absorption due to hydrophilicity and enzymatic instability in the gastrointestinal tract.'
Hydrophobic ion pairing as a first fix
The team's first move was to change the surface chemistry of the peptide through a process called hydrophobic ion pairing, abbreviated HIP. They combined semaglutide with a compound called sodium docusate, which is a small molecule with a fatty character. The two substances carry opposite electrical charges, so they are attracted to each other and form a tight complex held together by ionic bonds.
The resulting complex, referred to in the study as SET-DOC, is much more oil-friendly than the peptide alone. This matters because fat-soluble compounds can pass through intestinal membranes far more easily than water-soluble ones. The HIP step essentially gives the peptide a chemical disguise that makes it look more like a fat to the gut lining.
Critically, this kind of pairing is reversible. Once the complex reaches a more favorable environment beyond the intestinal barrier, the peptide can dissociate from the docusate and become active again. The researchers designed the pairing to be a delivery tool, not a permanent modification to the peptide's structure.
Self-microemulsifying delivery as a second fix
Changing the peptide's surface chemistry was only half the strategy. The team also needed to protect it physically during the journey through the gut and give it the best possible chance of reaching the intestinal wall intact. For this they used a self-emulsifying drug delivery system, which researchers in the field often shorten to SEDDS.
A SEDDS is a carefully blended mixture of oils, surfactants, and co-solvents that, when it contacts water, spontaneously organizes itself into an emulsion of extremely small droplets. In this study, the optimized formulation produced droplets averaging about 85 nanometers in diameter. At that scale, the droplets present a very large surface area relative to their volume, which is favorable for absorption.
The SET-DOC complex was loaded into this oil-based system, and the drug loading reached 2.64 milligrams per gram of formulation, which the researchers described as high for a peptide of this complexity. The finished product, called SD@SEDDS in the paper, also showed good physical stability, meaning the droplets did not clump or degrade rapidly under storage conditions.
Cell-model permeability results
Before moving to animals, the team tested how well SD@SEDDS crossed an intestinal barrier in the laboratory. They used a co-culture model combining two human intestinal cell lines, Caco-2 cells and HT-29 cells, grown together to create a more realistic simulation of the gut lining than either cell type alone.
The formulation showed enhanced permeability compared to unmodified semaglutide. The researchers also noted reduced activity of a protein called P-glycoprotein, which normally acts as a pump that pushes certain molecules back out of cells before they can be absorbed. By blunting this efflux mechanism, the formulation allowed more peptide to pass through rather than being ejected. These are in vitro findings, meaning they come from a lab dish rather than a living system, but they provide a mechanistic explanation for why the approach might work in a real gut.
Animal model outcomes
The most direct test came from experiments in rats with induced type 2 diabetes. When the rats received oral SD@SEDDS, the study recorded a significant reduction in blood glucose levels compared to control groups. The formulation also produced improvements in lipid profiles, a term covering measurements like triglycerides and cholesterol-related markers that are often disrupted in metabolic disease.
The researchers also assessed safety. They reported good biocompatibility and no observable toxicity in the animals at the doses studied. This does not mean the approach is proven safe in humans, since animal models have well-known limitations as predictors of human outcomes, but the absence of toxicity signals at this stage is a standard prerequisite before any further development.
It is worth noting that these are preclinical results. The gap between a promising rat study and a product that works reliably in human clinical trials is large, and many formulation strategies that succeed in animals do not replicate in humans. The researchers themselves frame the work as a 'promising strategy' rather than a finished solution.
Broader meaning for peptide research
The study contributes to a larger effort in pharmaceutical science to make peptide drugs orally available. The challenge is not unique to GLP-1 agonists. Many research peptides, from growth hormone secretagogues to anti-inflammatory sequences, face the same gut barrier problem. Any formulation method that reliably improves oral bioavailability would have implications well beyond a single compound.
The combination of hydrophobic ion pairing and self-emulsifying delivery is not entirely new as individual concepts, but this research demonstrates that layering the two strategies together can produce measurable benefits in a difficult case. The researchers suggest the approach could serve as a template for other peptide drugs with similar hydrophilicity and enzymatic stability challenges.
What remains to be worked out includes scaling the manufacturing process, confirming that the formulation behaves consistently across different physiological conditions such as fed versus fasted states, and eventually testing safety and effectiveness in human volunteers. Each of those steps is a significant research undertaking on its own.
